ImmuCell (NASDAQ:ICCC) Stock Price Passes Above 200-Day Moving Average – Should You Sell?

ImmuCell Co. (NASDAQ:ICCC) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $4.40 and traded as high as $4.97. ImmuCell shares last traded at $4.97, with a volume of 2,110 shares.

ImmuCell Price Performance

The company has a market capitalization of $44.29 million, a PE ratio of -9.94 and a beta of 0.62. The company has a current ratio of 3.11, a quick ratio of 1.44 and a debt-to-equity ratio of 0.36. The stock has a fifty day simple moving average of $5.18 and a 200-day simple moving average of $4.40.

ImmuCell (NASDAQ:ICCC) last posted its earnings results on Tuesday, February 25th. The biotechnology company reported $0.06 earnings per share for the quarter. The firm had revenue of $7.75 million during the quarter. ImmuCell had a negative return on equity of 15.32% and a negative net margin of 15.99%.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Mesirow Financial Investment Management Inc. lifted its position in ImmuCell by 100.0% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 24,356 shares of the biotechnology company’s stock valued at $125,000 after acquiring an additional 12,178 shares during the last quarter. Citadel Advisors LLC purchased a new position in shares of ImmuCell during the fourth quarter worth about $149,000. Northern Trust Corp increased its position in shares of ImmuCell by 51.0% during the fourth quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company’s stock worth $229,000 after purchasing an additional 14,982 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of ImmuCell by 13.9% in the 4th quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company’s stock valued at $332,000 after purchasing an additional 7,878 shares during the last quarter. Finally, Dauntless Investment Group LLC acquired a new stake in shares of ImmuCell in the 4th quarter valued at about $676,000. Institutional investors and hedge funds own 13.47% of the company’s stock.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.